Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 2002

View Archived Issues

Studies of pioglitazone in liver diseases discussed at AASLD meeting

Entecavir reportedly superior to lamivudine in HBV-infected patients

Amantadine in combination therapies for hepatitis C

Novel inhibitors of CDK and GSK-3 identified by Schering researchers

Series of histamine H3 antagonists for use in cognitive disorders reported by Abbott

Altana Pharma claims novel series of tryptase inhibitors with utility in airways disorders

New 5-HT2C agonists for erectile dysfunction and other disorders under study at Yamanouchi

IL-6 production inhibitors in early development at Ono

Novel substance P antagonists covered by Takeda patent

New alphavbeta3 antagonists in development at Dainippon

Potential use of vaccines in advanced prostate cancer

Albuferon in chronic hepatitis C

Zileuton reported to improve airways inflammation in cystic fibrosis

Symptom relief achieved with tiotropium in mild COPD

Oral factor Xa inhibitor enters phase I study for the treatment of thrombotic diseases

First approval obtained for Cialis

Endo and Durect to collaborate in the area of pain management

Bristol-Myers Squibb signs NF-kB license agreement with Ariad

CeNeS agrees to outlicense potential treatment for MS to Acorda

Neurocrine Biosciences reports positive results from phase III trial with indiplon-IR

Incyte Genomics to acquire Maxia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...